Landscape of germline pathogenic variants in patients with dual primary breast and lung cancer.
Breast cancer
Germline variants
Lung cancer
Multiple primary cancers
Whole-exome sequencing
Journal
Human genomics
ISSN: 1479-7364
Titre abrégé: Hum Genomics
Pays: England
ID NLM: 101202210
Informations de publication
Date de publication:
17 07 2023
17 07 2023
Historique:
received:
10
05
2023
accepted:
10
07
2023
medline:
19
7
2023
pubmed:
18
7
2023
entrez:
17
7
2023
Statut:
epublish
Résumé
Cancer predisposition is most often studied in the context of single cancers. However, inherited cancer predispositions can also give rise to multiple primary cancers. Yet, there is a paucity of studies on genetic predisposition in multiple primary cancers, especially those outside of well-defined cancer predisposition syndromes. This study aimed to identify germline variants associated with dual primary cancers of the breast and lung. Exome sequencing was performed on germline DNA from 55 Singapore patients (52 [95%] never-smokers) with dual primaries in the breast and lung, confirmed by histopathology. Using two large control cohorts: the local SG10K_Health (n = 9770) and gnomAD non-cancer East Asians (n = 9626); and two additional local case cohorts of early-onset or familial breast cancer (n = 290), and lung cancer (n = 209), variants were assessed for pathogenicity in accordance with ACMG/AMP guidelines. In particular, comparisons were made with known pathogenic or likely pathogenic variants in the ClinVar database, pathogenicity predictions were obtained from in silico prediction software, and case-control association analyses were performed. Altogether, we identified 19 pathogenic or likely pathogenic variants from 16 genes, detected in 17 of 55 (31%) patients. Six of the 19 variants were identified using ClinVar, while 13 variants were classified pathogenic or likely pathogenic using ACMG/AMP guidelines. The 16 genes include well-known cancer predisposition genes such as BRCA2, TP53, and RAD51D; but also lesser known cancer genes EXT2, WWOX, GATA2, and GPC3. Most of these genes are involved in DNA damage repair, reaffirming the role of impaired DNA repair mechanisms in the development of multiple malignancies. These variants warrant further investigations in additional populations. We have identified both known and novel variants significantly enriched in patients with primary breast and lung malignancies, expanding the body of known cancer predisposition variants for both breast and lung cancer. These variants are mostly from genes involved in DNA repair, affirming the role of impaired DNA repair in the predisposition and development of multiple cancers.
Sections du résumé
BACKGROUND
Cancer predisposition is most often studied in the context of single cancers. However, inherited cancer predispositions can also give rise to multiple primary cancers. Yet, there is a paucity of studies on genetic predisposition in multiple primary cancers, especially those outside of well-defined cancer predisposition syndromes. This study aimed to identify germline variants associated with dual primary cancers of the breast and lung.
METHODS
Exome sequencing was performed on germline DNA from 55 Singapore patients (52 [95%] never-smokers) with dual primaries in the breast and lung, confirmed by histopathology. Using two large control cohorts: the local SG10K_Health (n = 9770) and gnomAD non-cancer East Asians (n = 9626); and two additional local case cohorts of early-onset or familial breast cancer (n = 290), and lung cancer (n = 209), variants were assessed for pathogenicity in accordance with ACMG/AMP guidelines. In particular, comparisons were made with known pathogenic or likely pathogenic variants in the ClinVar database, pathogenicity predictions were obtained from in silico prediction software, and case-control association analyses were performed.
RESULTS
Altogether, we identified 19 pathogenic or likely pathogenic variants from 16 genes, detected in 17 of 55 (31%) patients. Six of the 19 variants were identified using ClinVar, while 13 variants were classified pathogenic or likely pathogenic using ACMG/AMP guidelines. The 16 genes include well-known cancer predisposition genes such as BRCA2, TP53, and RAD51D; but also lesser known cancer genes EXT2, WWOX, GATA2, and GPC3. Most of these genes are involved in DNA damage repair, reaffirming the role of impaired DNA repair mechanisms in the development of multiple malignancies. These variants warrant further investigations in additional populations.
CONCLUSIONS
We have identified both known and novel variants significantly enriched in patients with primary breast and lung malignancies, expanding the body of known cancer predisposition variants for both breast and lung cancer. These variants are mostly from genes involved in DNA repair, affirming the role of impaired DNA repair in the predisposition and development of multiple cancers.
Identifiants
pubmed: 37461096
doi: 10.1186/s40246-023-00510-7
pii: 10.1186/s40246-023-00510-7
pmc: PMC10353088
doi:
Substances chimiques
GPC3 protein, human
0
Glypicans
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
66Subventions
Organisme : NHGRI NIH HHS
ID : U54 HG003067
Pays : United States
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2023. The Author(s).
Références
Genes Chromosomes Cancer. 2017 Feb;56(2):128-134
pubmed: 27636706
JAMA. 2006 Sep 27;296(12):1469-78
pubmed: 17003395
Am J Med Genet A. 2014 Apr;164A(4):993-7
pubmed: 24459012
Eur J Cancer. 2002 Jul;38(11):1520-5
pubmed: 12110499
Front Oncol. 2019 Dec 20;9:1429
pubmed: 31921681
Nature. 2016 Aug 17;536(7616):285-91
pubmed: 27535533
Nat Methods. 2010 Aug;7(8):575-6
pubmed: 20676075
Semin Oncol. 2016 Oct;43(5):598-608
pubmed: 27899193
J Pathol. 2019 Sep;249(1):19-25
pubmed: 31056747
Nat Protoc. 2009;4(7):1073-81
pubmed: 19561590
Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):359-63
pubmed: 17379448
J Clin Oncol. 2021 May 20;39(15):1631-1640
pubmed: 33560870
Cancers (Basel). 2019 Mar 28;11(4):
pubmed: 30925779
Am J Med. 1994 Jun;96(6):516-20
pubmed: 8017449
Hum Genomics. 2022 Nov 23;16(1):61
pubmed: 36424660
Genes Dev. 2022 Mar 1;36(5-6):278-293
pubmed: 35318271
J Cancer Res Clin Oncol. 2018 Dec;144(12):2495-2513
pubmed: 30306255
NPJ Genom Med. 2016 Jan 13;1:15003
pubmed: 29263802
Nat Genet. 2020 Feb;52(2):177-186
pubmed: 32015526
Nat Rev Clin Oncol. 2016 Sep;13(9):581-8
pubmed: 27296296
Cancers (Basel). 2020 Mar 30;12(4):
pubmed: 32235514
BMC Med. 2022 Oct 6;20(1):332
pubmed: 36199081
Cancer Epidemiol Biomarkers Prev. 2022 Jul 1;31(7):1450-1459
pubmed: 35477182
Oncologist. 2007 Jan;12(1):20-37
pubmed: 17227898
J Natl Compr Canc Netw. 2020 Apr;18(4):380-391
pubmed: 32259785
Genet Med. 2019 Feb;21(2):426-430
pubmed: 29875428
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
J Natl Cancer Inst. 1983 Sep;71(3):455-61
pubmed: 6577220
J Pediatr Surg. 2022 Mar;57(3):430-442
pubmed: 34503817
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Breast Cancer Res Treat. 2015 Sep;153(2):435-43
pubmed: 26296701
JCO Precis Oncol. 2021 Nov;5:577-584
pubmed: 34994607
JAMA. 2018 Sep 25;320(12):1266-1274
pubmed: 30264118
Transl Lung Cancer Res. 2020 Jun;9(3):646-658
pubmed: 32676327
Nature. 2023 Apr;616(7955):159-167
pubmed: 37020004
Int J Cancer. 2019 Apr 15;144(8):1962-1974
pubmed: 30303537
Cancer. 2003 Mar 15;97(6):1404-11
pubmed: 12627503
Am J Hum Genet. 2018 Jul 5;103(1):3-18
pubmed: 29909963
Front Oncol. 2018 Oct 09;8:427
pubmed: 30356721
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Int J Mol Sci. 2015 Dec 10;16(12):29643-53
pubmed: 26690424
Am J Hum Genet. 2016 Oct 6;99(4):877-885
pubmed: 27666373
Nat Genet. 2014 Mar;46(3):310-5
pubmed: 24487276
Cancers (Basel). 2022 Mar 24;14(7):
pubmed: 35406420
Cancer Lett. 2009 Jan 8;273(1):172-6
pubmed: 18789574
Cancer Lett. 2015 Dec 28;369(2):274-88
pubmed: 26427841
JAMA Oncol. 2017 Sep 01;3(9):1190-1196
pubmed: 28418444
JAMA. 2011 Jun 8;305(22):2304-10
pubmed: 21642682
Nat Commun. 2020 Apr 2;11(1):1640
pubmed: 32242007
Nucleic Acids Res. 2023 Jan 6;51(D1):D384-D388
pubmed: 36477806
JCO Precis Oncol. 2017 Nov;1:1-12
pubmed: 35172496
J Clin Oncol. 2020 Aug 20;38(24):2728-2740
pubmed: 32496904
ESMO Open. 2017 May 2;2(2):e000172
pubmed: 28761745
Curr Protoc Hum Genet. 2013 Jan;Chapter 7:Unit7.20
pubmed: 23315928